Genentech leukemia drug passes big test vs. blockbuster Rituxan

An experimental leukemia drug from Genentech Inc. helped patients in a late-stage trial live longer without their disease progressing than those given the biotech company’s blockbuster cancer treatment Rituxan...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.